scPharmaceuticals Inc. (SCPH)
| Market Cap | 163.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.21M |
| Shares Out | 24.57M |
| EPS (ttm) | -1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $5.84 |
| Previous Close | $6.06 |
| Change ($) | -0.22 |
| Change (%) | -3.63% |
| Day's Open | 6.06 |
| Day's Range | 5.74 - 6.05 |
| Day's Volume | 50,318 |
| 52-Week Range | 5.06 - 11.99 |
ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional cli...
BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch investors are ad...
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult pati...
Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-based...
BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration
BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...
scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
scPharmaceuticals has created proprietary formulations of widely used, generically available IV drugs that can be more easily administered subcutaneously.
The pharmaceutical company priced a secondary offering to raise capital.
Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020
About SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an anti... [Read more...]
| Industry Biotechnology | IPO Date Nov 17, 2017 |
| CEO John Tucker | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol SCPH |
Analyst Forecasts
According to 4 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is 12.33, which is an increase of 111.13% from the latest price.